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1 |  INTRODUCTION
Pulmonary hypertension (PH) is a progressive disease char-
acterized by an elevated pulmonary arterial pressure and 
pulmonary vascular resistance. As a consequence of the el-
evated pulmonary arterial pressure, patients are at risk of 
right heart failure and death. Patients with connective tis-
sue diseases (CTD) such as systemic sclerosis (SSc), mixed 
connective tissue disease (MCTD) and systemic lupus er-
ythematosus (SLE) may develop PH as a complication of 
their autoimmune disease.1 Also in patients suffering from 
CTDs, the occurrence of PH has a major impact on quality 
of life and prognosis. In the last years, our knowledge on 
risk factors, screenings modalities and treatment options has 
increased and prognosis has improved. In this narrative re-
view, PH in CTD is discussed, with the focus on pulmonary 
arterial hypertension (PAH), taken up-to-date knowledge on 
screening, early diagnosis, treatment options and prognosis 
into account.
2 |  CLINICAL PRESENTATION 
AND DIAGNOSIS
Pulmonary hypertension is a severe clinical condition in 
which loss and obstructive remodelling of the pulmonary 
vascular bed is responsible for the rise of pulmonary arterial 
pressure (PAP) and pulmonary vascular resistance (PVR), 
resulting in progressive right heart failure and functional 
decline.2 Patients with CTD such as SSc, MCTD and SLE 
are at risk of PH; with PAH being the most progressive form 
of PH, but also other forms of PH occur and CTD patients 
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Abstract
Pulmonary arterial hypertension is a lethal complication of different connective tis-
sue diseases such as systemic sclerosis, mixed connective tissue disease and systemic 
lupus erythematosus. Although the treatment possibilities for patients with pulmo-
nary arterial hypertension have increased in the last two decades and survival of pa-
tients with idiopathic pulmonary arterial hypertension has improved, the latter is not 
the case for patients with pulmonary arterial hypertension associated with connective 
tissue disease. In this narrative review, we review recent literature and describe the 
improvement of early diagnostic possibilities, screening modalities and treatment op-
tions. We also point out the pitfalls in diagnosis in this patient category and describe 
the unmet needs and what the focus of future research should be.
K E Y W O R D S
connective tissue disease, pulmonary hypertension, systemic lupus erythematosus, systemic 
sclerosis
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often suffer from overlap of different forms of PH.1 The 
first signs and symptoms of PAH are generally vague and 
nonspecific. Patients experience fatigue, dyspnoea on exer-
tion, weakness and light headedness. Those symptoms are 
often ascribed to the CTD itself or to having a low physi-
cal fitness. More severe symptoms such as (near) syncope, 
angina and/or oedema only occur after extensive pulmonary 
vasculopathy has developed. The diagnostic approach in pa-
tients with a clinical suspicion for PH should include physi-
cal examination, laboratory work-up, pulmonary function 
testing including forced vital capacity (FVC) and diffusion 
capacity for carbon monoxide (DLCO), echocardiography, 
high-resolution chest computed tomography scan and ven-
tilation/perfusion lung scanning as the differential diagno-
sis of PAH should be taken into account.3 Blood tests are 
not useful for the diagnosis of PH but may help distinguish 
forms of PH and prognosis, such as an elevated N-terminal 
pro-BNP (NT-pro-BNP) level.3 Pulmonary function tests 
including total lung capacity, FVC and DLCO reveal a mild 
restrictive component with a marked reduction of DLCO in 
PAH.3 Echocardiography shows a dilated and hypertrophic 
right ventricle with signs of pressure overload such as sys-
tolic septal flattening. Using the regurgitant velocity of tri-
cuspid regurgitation and pulmonary regurgitation and the 
shape of the velocity curve of the right ventricular outflow 
tract velocity, systolic, diastolic and mean pulmonary arte-
rial pressures can be estimated. Together with the echocar-
diographic estimation of right atrial pressure, cardiac index 
and left atrial pressures, a fairly accurate impression of 
pulmonary haemodynamics can be obtained.4 Ventilation/
perfusion lung scanning is the preferred diagnostic tool for 
chronic embolic disease.3 The high-resolution chest com-
puted tomography may show parenchymal lung disease.3 
The gold standard to diagnose all forms of PH is a right heart 
catheterization performed as described by the European col-
lege of cardiologist guidelines.1
3 |  CLASSIFICATION
Pulmonary hypertension is diagnosed by right heart cath-
eterization (RHC), revealing a mean pulmonary arterial 
pressure (PAP) ≥25 mm Hg.1,5 With right heart catheteriza-
tion, PH can be divided into three groups: pre-capillary PH, 
isolated post-capillary PH (IpcPH) and combined pre- and 
post-capillary PH (CpcPH) by estimation of the pulmonary 
arterial wedge pressure (PAWP) and pulmonary vascular 
resistance (PVR). The characteristics are summarized in 
Table 1.
Besides this hemodynamic classification, a clinical 
classification is used. The purpose of clinical classifica-
tion of PH is to categorize clinical conditions associated 
with PH based on similar pathophysiological mechanisms, 
clinical presentation, hemodynamic characteristics and 
therapeutic management.5 The 2018 updated clinical clas-
sification of pulmonary hypertension is summarized in 
Table 2.
Different forms of pulmonary hypertension may occur in 
patients with connective tissue diseases. The most progres-
sive form of PH, group 1 PAH, occurs as a consequence of 
remodelling and constriction of the pulmonary arteries and 
arterioles, leading to a progressive increase of the pulmonary 
vascular resistance and right heart failure.6 It is currently 
accepted that inflammatory mechanisms contribute to PAH 
genesis and progression, especially in patients with CTD.7,8 
Inflammatory cell infiltrates have been detected in plexiform 
lesions from patients with CTD-associated PAH.9 In fact, 
CTDs are the major cause of PAH, occupying around one-
fourth of the total PAH population.10 Group 2 PH, which is 
PH associated with impaired left heart function, may occur 
as a consequence of CTD as well. As interstitial lung dis-
ease is another common complication of CTDs, especially 
of SSc and MCTD, group 3 PH may also be contributed to 




















Abbreviations: mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, 
pulmonary vascular resistance; WU, Wood units.
aGroup 1: PAH; group 2: PH due to left heart disease; group 3: PH due to lung diseases and/or hypoxia; group 
4: due to pulmonary artery obstructions; group 5: PH with unclear and/or multifactorial mechanisms. 
T A B L E  1  Hemodynamic definitions of 
pulmonary hypertension (PH)5
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associated with CTD as well. Of note is pulmonary veno-oc-
clusive disease which shares the same hemodynamic profile 
and clinical presentation as other forms of PAH. However, 
it is associated with a more pronounced venous/capillary in-
volvement and is associated with a poor prognosis, a limited 
response to PAH therapy and a risk of pulmonary oedema 
with these treatments.5,11 This form of PAH occurs especially 
in SSc. The localization of the different forms of PH is shown 
in Figure 1.
4 |  EPIDEMIOLOGY OF PAH IN 
CONNECTIVE TISSUE DISEASES
Pulmonary arterial hypertension may occur as a complication 
of various CTDs, such as SSc, MCTD, SLE, primary Sjogren 
syndrome and (dermato-) myositis. Among the CTDs, SSc 
has the highest known PAH prevalence. PAH affects approx-
imately 8%-12% of patients with SSc and has an incidence 
of 0.61 cases per 100 patient years.12,13 The prevalence of 
PAH in non-SSc CTDs remains to be determined due to the 
lack of large, RHC based cohort studies but is estimated to be 
lower than in SSc patients.14 Based on a nationwide cohort 
study in Taiwan and a systematic review of the literature, the 
prevalence of PAH in SLE is <4%.15,16 For the other CTDs, 
the prevalence is estimated to be <1%.1
5 |  PROGNOSIS
The prognosis of patients with certain forms of PH has in-
creased with the availability of several vasoactive drugs, bet-
ter supportive care, earlier diagnosis and earlier treatment. A 
number of studies and registries have shown a less favourable 
outcome of patients with PAH associated with SSc compared 
to those with idiopathic PAH or non-SSc CTD-associated 
PAH.17,18 The 3-year survival rate of PAH associated with 
SSc is estimated to be only 52%, despite the available tar-
geted treatments.19 The survival of SLE-PAH, studied in 
a nationwide cohort study in France, is better, with 3- and 
5-year overall survival rates of 89.4% and 83.9%, respec-
tively.20 In this study, risk factors of death were found to be 
renal involvement and elevated PVR. In 2 other cohort stud-
ies, the presence of anti-U1-RNP antibodies was found to be 
protective factors for survival.21,22
6 |  EARLY DIAGNOSIS OF 
PULMONARY ARTERIAL 
HYPERTENSION
The symptoms of PAH are nonspecific, especially in CTD 
patients. Breathlessness, fatigue, weakness, angina and syn-
cope are seen initially during exertion and in advanced cases 
at rest. Abdominal distension and ankle oedema are signs of 
progressing right ventricular failure.1
Pulmonary arterial hypertension may occur in both lim-
ited cutaneous and diffuse cutaneous SSc, and in patients 
with a short disease duration and a long disease duration.23 
In SSc patients without skin involvement yet (‘early’ SSc), 
only limited date are available in literature.24 In a Belgian 
cohort, none of the 84 included SSc patients without skin 
involvement were diagnosed with PAH.25 Mortality in 
SSc-PAH is high, and mortality rates are the highest in the 





1.3 Drug and toxin-induced PAH
1.4 PAH associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.5 PAH with long-term responders to calcium channel blockers
1.6 PAH with overt features of venous/capillaries (PVOD/PCH) 
involvement
1.7 Persistent PH of the newborn syndrome
2 PH due to left heart disease
2.1 PH due to heart failure with preserved LVEF
2.2 PH due to heart failure with reduced LVEF
2.3 Vascular heart disease
2.4 Congenital/acquired cardiovascular conditions leading to 
post-capillary PH
3 PH due to lung diseases and/or hypoxia
3.1 Obstructive lung disease
3.2 Restrictive lung disease
3.3 Other lung disease with mixed restrictive/obstructive pattern
3.4 Hypoxia without lung disease
3.5 Developmental lung disorders
4 PH due to pulmonary artery obstructions
4.1 Chronic thromboembolic PH
4.2 Other pulmonary artery obstructions
5 PH with unclear and/or multifactorial mechanism
5.1 Haematological disorders
5.2 Systemic and metabolic disorders
5.3 Others
5.4 Complex congenital heart disease
Abbreviations: LVEF, left ventricular ejection fraction; PAH, pulmonary arterial 
hypertension; PCH, pulmonary capillary haemangiomatosis; PVOD, pulmonary 
veno-occlusive disease.
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SSc patients who are most severely ill (defined by the New 
York Heart Association functional class [NYHA FC]) at 
the moment of PAH diagnosis. In a French registry, the 
3-year survival rate was 30%-72% in the SSc-PAH patients 
diagnosed in NYHA FC III/IV whereas the 3-year sur-
vival rate was up to 80% when diagnosed in NYHA FC II. 
However, most of the patients were diagnosed in NYHA 
FC III/IV and only a minority in NYHA FC II at diagno-
sis.26 Systematic screening of SSc patients leads to earlier 
diagnosis of PAH. Data from a French and an Australian 
screening programme showed that the SSc patients diag-
nosed with PAH by screening had lower NYHA FC (≥50% 
of the included SSc-PAH patients were in NYHA FC I/II 
at diagnosis, in both cohorts) and lower pulmonary vascu-
lar resistance on right heart catheterization as compared 
to those who were diagnosed by symptoms.27,28 Therefore, 
early diagnosis is key to improve survival in PAH patients. 
Screening results in earlier diagnosis and thus earlier 
treatment. International guidelines recommend screening 
for PAH in SSc patients from 2009 onwards. Evidence has 
F I G U R E  1  A schematic view of 
the pulmonary vasculature. A, aorta; 
ILD, interstitial lung disease; LAP, left 
artrial pressure; LV, left ventricle; PAH, 
pulmonary arterial hypertension; PVOD, 
pulmonary veno-occlusive disease; RA, 








F I G U R E  2  Echocardiography and pulmonary hypertension. A’, active diastolic velocity of the tricuspid annulus; Ao, aorta; E’, early diastolic 
velocity of the tricuspid annulus; IVC, inferior vena cava; LA, left atrium; LV, left ventricle; RA; right atrium; RV, right ventricle; RVOT, right 
ventricular outflow tract; S’, systolic velocity of tricuspid annulus; TRPG, tricuspid regurgitation pressure gradient. Adapted from 51
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been accumulating that screening results in improved sur-
vival in SSc patients.1,3,27,29,30 Different screening methods 
are used and recommended, based on clinical evaluation, 
pulmonary function testing, echocardiography, biomarkers 
or a combination of parameters.1,3,27,29,30 For patients with 
SSc and a disease duration of >3 years and a DLCO a% 
the DETECT algorithm is used. This DETECT algorithm 
consists of a 2-step diagnostic algorithm with clinical, 
laboratory, lung functional and electrocardiographic pa-
rameters in step 1 and echocardiography in step 2, result-
ing in advice to perform a RHC or not.31 This algorithm 
has proved to reduce the number of missed diagnoses of 
PAH in SSc compared to using only echocardiography and 
symptoms.31 For all SSc patients, the appropriate screen-
ing tools include the 2015 European Society of Cardiology 
(ESC)/European Respiratory Society (ERS) echocardio-
graphic recommendations (Figure 2), and a combination 
of a FVC/DLCO  >  1.6 and a N-terminal pro-BNP  >  2 
times upper limit of normal. For high-risk patients (dis-
ease duration > 3 years and DLCO < 60% of predicted), 
the DETECT algorithm can be used as indicator for refer-
ral for RHC.1,3,30 Current guidelines and recommendations 
also recognize patients along the SSc spectrum such as 
MCTD, who have other CTDs but with features of SSc, as 
needing to be screened similar to patients with SSc.1,3,30,32 
In other CTDs, systematic screening for PAH is not rec-
ommended given its low prevalence. However, for SLE-
associated PAH, several risk factors for PAH have been 
identified, consisting of longer disease duration of SLE, 
the presence of interstitial lung disease, the absence of skin 
rash, the presence of pericardial effusion, the presence of 
anti-RNP or anti-SSA antibodies, low disease activity, low 
ESR and elevated uric acid.21 Careful monitoring of those 
patients is recommended.
7 |  TREATMENT OF PAH
The treatment of PAH in patients with CTDs is a complex 
strategy based on initial evaluation of severity and prog-
nostic risk, as well as subsequent response to treatment.33,34 
Patients with PH are to be referred to expert centres and 
treated by a multidisciplinary team consisting of rheuma-
tologists, cardiologists and chest physicians as well as spe-
cialized nurses. As PAH has a severe impact on daily living 
and is life-threatening, psychological, social and emotional 
support is advocated which is often provided for by the 
specialized nurses.35 General measures for PAH associated 
with CTD consist of encouragement of physical activity 
within limits, vaccination against influenza and pneumo-
coccal pneumonia, iron substitution if indicated, the use of 
diuretics in patients with signs of fluid retention and oxy-
gen when applicable.1,34
The use of high-dose calcium channel blockers (CCB) in 
CTD-PAH is not recommended. However, the majority of the 
SSc patients already take CCB for Raynaud's phenomenon.36 
In contrast to patients suffering from idiopathic PAH, oral 
anticoagulant therapy is not recommended.1
According to the ESC/ERS guidelines, in patients with 
CTD-PAH, the same treatment algorithm as for patients with 
idiopathic PAH is recommended. Currently approved treat-
ment strategies in PAH target three main pathways: the pros-
tacyclin pathway, the endothelin pathway and the nitric oxide 
(NO) pathway.1,34
7.1 | Prostacyclin pathway
Prostacyclin analogues bind to the prostacyclin receptor 
leading to an increase of cyclic adenosine monophosphate 
(cAMP), resulting in vasodilation, antiproliferative and an-
tithrombotic effects.1 Four agents have been licensed by 
the Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) for treatment of PAH: epopros-
tenol (iv), treprostenil (iv, sc, inhaled), iloprost (inhaled) and 
selexipag, an orally active, selective prostacyclin receptor 
agonist.
7.2 | Endothelin pathway
Endothelin-1 (ET-1) acts through two receptor subtypes 
namely ET receptor type A and B. ET-1 causes vasoconstric-
tion and proliferation of the smooth muscle cells by bind-
ing to ET type A and B receptor and increases the NO and 
prostacyclin production by binding to ET type B receptor.1 
Bosentan and macitentan are nonselective ET-1 receptor 
antagonists (ERA), while ambrisentan is a selective type A 
ET-1 receptor antagonist.1
7.3 | Nitric oxide pathway
Reduced nitric oxide (NO) availability is associated with 
PAH. NO induces vasodilation and inhibits vascular prolifera-
tion by increasing production of cyclic guanosine monophos-
phate (cGMP). Phosphodiesterases (PDEs) are enzymes that 
inactivate cGMP. Phosphodiesterase five inhibitors (PDE5-I) 
(sildenafil and tadalafil) slow the breakdown of cGMP and 
the soluble guanylate cyclase agonist (riociguat) stimulates 
cGMP production.1
In most of the randomized controlled trials (RCT) on 
which approval of specific PAH treatment is based, both 
idiopathic PAH and CTD-PAH patients are included (up to 
30% CTD-PAH patients). Focusing on CTD-PAH and SSc-
PAH, there are some general remarks and limitations. RCTs 
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T A B L E  3  Clinical trials or subgroup analysis of clinical trials on CTD-PAH and SSc-PAH
Drug Reference
Type of study Inclusion 
criteria Treatment Comp N PAH N IPAH N CTD (N SSc-PAH) primary endpoint
Effect in CTD-PAH or 
SSc-PAH
Prostacyclins





Placebo 111 0 111 (111) placebo-corrected Δmedian 6 MWT at 
week 12
SSc
108 m (95%CI: 55.2 to 180 m)





97 0 97 (97) 1-, 2-, 3-year survival SSc
71%, 52% and 48%






Placebo 90 0 90 (45) placebo-corrected Δ6MWT at week 12 CTD
25 m (P = .055)
Selexipag Gaine 2017 
GRIPHON
39





Placebo 334 0 334 (170) Combined mortality/morbidity endpoint 










Bosentan po 125-250 mg 
2x/d
Placebo 213 150 63(47) ∆6MWT at week 16 SSc
43 m (95%CI: NA, P = NS)
Denton 200656 Subgroup analysis of an open-
label extension of 2 RCTs
CTD-PAHb , 6MWT 150-
500 m, WHO FC III/IV
Bosentan po 125-250 mg 
2x/d
Placebo 66 0 66 (52) placebo-corrected ∆6MWT at week 12-16 CTD
22.1 m (95%CI: −32 to 76 m)
Survival: 85.9% after 1 y and 










Placebo 742 404 224 combined mortality/morbidity primary 
endpoint (median duration of treatment: 
115 weeks)
HR (95%CI)
CTD: 0.58 (0.33 to 1.02)
Ambrisentan Galie 2008 ARIES-1 
and ARIES-257
2 RCTs















placebo-corrected ∆6MWT at week 12 CTD
range: 15 to 23 m
NO pathway






Placebo 84 0 84 (38) Placebo-corrected Δ6MWT at week 12
20 mg, 40 mg or 80 mg
CTD
20 mg: 55 m (95%CI: 24 to 
85 m), P < .01, 40 mg: 49 m 
(95%CI: 19 to 80 m), P < .01, 










Placebo 405 247 95 Placebo-corrected Δ6MWT at week 16
2.5 mg, 10 mg, 20 mg, 40 mg
CTD
2.5 mg: 18 m (95%CI: −27 to 
63 m), 10 mg: 22 m (95% CI: 
−13 to 56 m), 20 mg: 50 m 
(95% CI: 16 to 83 m), 40 mg: 
49 m (95%CI: 15 to 83 m)
Riociguat Ghofrani 2013
PATENT-160






Placebo 443 272 111 Placebo-corrected Δ6MWT at week 12
2.5 mg 3x/d
CTD
27 m (95%CI: −7 to 61 m)
Combination therapy
(Continues)
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T A B L E  3  Clinical trials or subgroup analysis of clinical trials on CTD-PAH and SSc-PAH
Drug Reference
Type of study Inclusion 
criteria Treatment Comp N PAH N IPAH N CTD (N SSc-PAH) primary endpoint
Effect in CTD-PAH or 
SSc-PAH
Prostacyclins





Placebo 111 0 111 (111) placebo-corrected Δmedian 6 MWT at 
week 12
SSc
108 m (95%CI: 55.2 to 180 m)





97 0 97 (97) 1-, 2-, 3-year survival SSc
71%, 52% and 48%






Placebo 90 0 90 (45) placebo-corrected Δ6MWT at week 12 CTD
25 m (P = .055)
Selexipag Gaine 2017 
GRIPHON
39





Placebo 334 0 334 (170) Combined mortality/morbidity endpoint 










Bosentan po 125-250 mg 
2x/d
Placebo 213 150 63(47) ∆6MWT at week 16 SSc
43 m (95%CI: NA, P = NS)
Denton 200656 Subgroup analysis of an open-
label extension of 2 RCTs
CTD-PAHb , 6MWT 150-
500 m, WHO FC III/IV
Bosentan po 125-250 mg 
2x/d
Placebo 66 0 66 (52) placebo-corrected ∆6MWT at week 12-16 CTD
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Survival: 85.9% after 1 y and 










Placebo 742 404 224 combined mortality/morbidity primary 
endpoint (median duration of treatment: 
115 weeks)
HR (95%CI)
CTD: 0.58 (0.33 to 1.02)
Ambrisentan Galie 2008 ARIES-1 
and ARIES-257
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(95%CI: 19 to 80 m), P < .01, 










Placebo 405 247 95 Placebo-corrected Δ6MWT at week 16
2.5 mg, 10 mg, 20 mg, 40 mg
CTD
2.5 mg: 18 m (95%CI: −27 to 
63 m), 10 mg: 22 m (95% CI: 
−13 to 56 m), 20 mg: 50 m 
(95% CI: 16 to 83 m), 40 mg: 
49 m (95%CI: 15 to 83 m)
Riociguat Ghofrani 2013
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2.5 mg 3x/d
CTD
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(Continues)
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on treatment of PAH in SSc and CTD are scarce and in the 
RCTs including both idiopathic PAH and CTD-PAH, sub-
group analysis of the CTD-PAH or SSc-PAH subgroup are 
not always performed or the subgroups were not powered 
to detect statistical significance. An important evolution in 
the PAH RCT design is the shifting of the primary endpoint 
from a short-term correlates such as the six minutes walking 
test (6MWT) to a long-term true clinical efficacy measure 
such as time to clinical worsening or a combined mortality/
morbidity endpoint.37-39 It is known that CTD patients also 
have many comorbidities such as myositis, arthritis, digital 
ulcers at the toes and fatigue interfering with the utility of 
the 6MWT.34
Table  3 focuses on the clinical trials or subgroup 
analyses of clinical trials on treatment of CTD-PAH and 
SSc-PAH. For the first RCTs and subgroup analyses with 
Drug Reference
Type of study Inclusion 
criteria Treatment Comp N PAH N IPAH N CTD (N SSc-PAH) primary endpoint













Po ambrisentan 10 mg or
Tadalafil 40 mg
187 0 187 (118) combined mortality/morbidity primary 





Abbreviations: %, per cent; 6MWT, six-minute walk test; CI, confidence interval; comp, comparator; CTD, connective tissue disease; CTD-PAH or SSc-PAH;  
ERA, endothelin-1 receptor antagonist; FC, functional class; HR, hazard ratio; IPAH, idiopathic pulmonary arterial hypertension; IV, intravenous; m, metre;  
mg, milligram; N, number of; NA, not available; NO, nitric oxide; NS, not significant; NYHA, New York Heart Association; others, other causes of PAH than IPAH;  
PAH, pulmonary arterial hypertension; po, per oral; RCT, randomized controlled trial; SC, subcutaneous; SSc, systemic sclerosis;  
WHO, World Health Organization; Δ, delta.
aPAH defined as mean pulmonary arterial pressure ≥35 mm Hg. 
bPAH defined as mean pulmonary arterial pressure ≥25 mm Hg. 
T A B L E  3  (Continued)
T A B L E  4  Risk assessment in pulmonary arterial hypertension
Determinants of prognosisa 
(estimated 1-year mortality Low risk < 5%
Intermediate risk 
5%-10% High risk > 10%
Clinical signs of right heart failure Absent Absent Present
Progression of symptoms No Slow Rapid
Syncope No Occasional syncopeb Repeated syncopec 
WHO Functional Class I-II III IV
6-minute walking distance >440 m 165-440 m <165 m
Cardiopulmonary exercise test Peak VO2 > 15 mL/min/kg
(>65% predicted)
Ve/VCO2-slope < 36
Peak VO2 11 - 15 mL/
min/kg
(35%-65% predicted)










Imaging (echo, CMR) RA area < 18 cm2
No pericardial effusion
RA area 18-26 cm2













Abbreviations: 6MWD, 6-minute walking distance; BNP ¼, brain natriuretic peptide; CI, cardiac index; CMR, cardiac magnetic resonance; NT-pro-BNP, N-terminal 
pro-brain natriuretic peptide; pred., predicted; RA, right atrium; RAP, right atrial pressure; SvO2, mixed venous oxygen saturation; VE/VCO2, ventilatory equivalents 
for carbon dioxide; VO2, oxygen consumption; WHO, World Health Organization.
aMost of the proposed variables and cut-off values are based on expert opinion. They may provide prognostic information and may be used to guide therapeutic 
decisions, but application to individual patients must be done carefully. One must also note that most of these variables have been validated mostly for idiopathic PAH 
and the cut-off levels used above may not necessarily apply to other forms of PAH. Furthermore, the use of approved therapies and their influence on the variables 
should be considered in the evaluation of the risk. 
bOccasional syncope during brisk or heavy exercise, or occasional orthostatic syncope in an otherwise stable patient. 
cRepeated episodes of syncope, even with little or regular physical activity. Adapted from the ESC/ERS guidelines on pulmonary hypertension.1 
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6MWT as primary endpoint, lower response rates are seen 
in CTD-PAH as compared to idiopathic PAH. However, 
from 2013 onwards, the SERAPHIN, the GRIPHON and 
the AMBITION trial used a combined mortality/morbid-
ity primary endpoint, consisting of time from the initia-
tion of treatment to the first event (death from any cause, 
worsening of PAH and need for additional treatment for 
PAH, lung transplantation or atrial septostomy).37-39 In the 
SERAPHIN and GRIPHON trial, the majority of the pa-
tients was already treated with PAH-specific therapy and 
in the AMBITION trial initial combination therapy was 
compared to initiation with monotherapy. In the subgroup 
analyses of CTD-PAH patients in all of these three tri-
als, there was a reduction of combined primary endpoint 
(Table 3).37-39
Following the international guidelines, in patients with 
CTD-PAH with NYHA FC II or III, initial oral combina-
tion therapy is started (ERA  +  PDE5-i), while those in 
NYHA FC IV are treated with initial combination therapy 
including parenteral prostacyclin (epoprostenol). There is 
no evidence of a favourable effect of treatment with immu-
nosuppression in SSc-associated PAH. However, treatment 
with immunosuppressive drugs, consisting of six monthly 
intravenous pulses of cyclophosphamide and a tapering 
dosage of prednisolone in SLE and MCTD-associated PAH 
has resulted in a clinical response in 50% of 16 patients.40 
Furthermore, the French nationwide SLE-PAH study 
showed a trend towards better survival in patients who re-
ceived hydroxychloroquine.20
8 |  TREAT TO TARGET
Risk status for mortality of Idiopathic PAH patients can be 
assessed by a comprehensive tool described by the ESC and 
the ERS guidelines.33,41 Risk criteria are based on the pres-
ence of clinical signs of right heart failure, progression of 
symptoms, the WHO functional class, the 6MWT, parame-
ters of cardiopulmonary exercise testing, NT-pro-BNP level, 
presence of right atrial dilatation and pericardial effusion on 
imaging, and (invasive) haemodynamics. For each criterium, 
values are set to assign a low, intermediate or high risk of 
estimated mortality.41-43 The average score of the number 
of low-risk criteria at baseline and during the first follow-
up discriminates the risk of death or lung transplantation and 
enables classification of patients as low (<5%), intermedi-
ate (5%-10%) or high risk (>10%) for an estimated 1-year 
mortality. Several studies investigated the validity of this 
scoring system by either using noninvasive criteria only or a 
combination of the noninvasive and invasive criteria.43,44 In 
these studies, it became clear that this scoring system is valid 
and that the quantification of the number of low-risk criteria 
present accurately predicts transplant-free survival in PAH 
(Table 4). Changes in risk from initial evaluation to first fol-
low-up also predict survival. Although PAH associated with 
CTD is a more progressive disease as idiopathic PAH, this 
risk stratification tool is valid for PAH-CTD as well.42 This 
instrument may help the clinician to intensify treatment by 
adding a third treatment modality and/or to start parenteral 
treatment with prostacyclin analogues if indicated. Of note is 
that lung transplantation is an option for eligible patients with 
CTDs as well.45
9 |  UNMET NEEDS
Pulmonary arterial hypertension is a well-known complica-
tion in CTDs, particularly in SSc. Ten per cent of the SSc 
patients will develop PAH during lifetime. However, di-
agnosing PAH is challenging since SSc patients may have 
group 1 PAH, group 2 PH secondary to left heart disease 
(due to myocardial fibrosis), group 3 PH secondary to inter-
stitial lung disease, group 4 PH (CTEPH), pulmonary veno-
occlusive disease or a combination as shown in Table 2.1,46 
Although the number of treatments is increasing also for 
PAH-CTD, mortality in especially SSc-PAH remains high, 
with lower survival rates and lower response rate of the PAH-
specific therapy as compared to idiopathic PAH.19
Drug Reference
Type of study Inclusion 
criteria Treatment Comp N PAH N IPAH N CTD (N SSc-PAH) primary endpoint













Po ambrisentan 10 mg or
Tadalafil 40 mg
187 0 187 (118) combined mortality/morbidity primary 





Abbreviations: %, per cent; 6MWT, six-minute walk test; CI, confidence interval; comp, comparator; CTD, connective tissue disease; CTD-PAH or SSc-PAH;  
ERA, endothelin-1 receptor antagonist; FC, functional class; HR, hazard ratio; IPAH, idiopathic pulmonary arterial hypertension; IV, intravenous; m, metre;  
mg, milligram; N, number of; NA, not available; NO, nitric oxide; NS, not significant; NYHA, New York Heart Association; others, other causes of PAH than IPAH;  
PAH, pulmonary arterial hypertension; po, per oral; RCT, randomized controlled trial; SC, subcutaneous; SSc, systemic sclerosis;  
WHO, World Health Organization; Δ, delta.
aPAH defined as mean pulmonary arterial pressure ≥35 mm Hg. 
bPAH defined as mean pulmonary arterial pressure ≥25 mm Hg. 
T A B L E  3  (Continued)
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In CTDs in general, patients suffer from different lim-
itations and morbidity due to their disease and often ex-
perience alternating periods of more and less disease 
activity resulting in fatigue and reduced exercise tolerance. 
As a result, complaints of constitutional symptoms do not 
prompt the patients to seek medical help. It is therefore 
challenging to make an early diagnosis of PH in patients 
with CTDs. The 6th world symposium on PH task force 
proposed to change the haemodynamic definition of PH. A 
mean PAP > 20 mm Hg and PVR ≥ 3 Woods Unit instead 
of mean PAP ≥ 25 mm Hg. 1,5 Although patients with bor-
derline PAP (mean PAP 21-24  mm  Hg) did not need any 
PAH-specific treatment, the 2015 ESC/ERS guidelines 
recommended close monitoring of these patients to detect 
the possible progression to PH, because of a higher risk of 
PAH.1 Many patients with borderline PAP have a mild stage 
of pulmonary vasculopathy and are at increased risk for de-
veloping PH.47-50 In SSc, PAH is known as a complication 
with high prevalence, late diagnosis and high mortality. In 
the last decade, progression has been made in screening 
purposes for PAH in SSc, in organization of expert centres 
for PAH and SSc and in the importance of early start of ini-
tial combination therapy.
Another challenging aspect of PAH-CTD is that patients 
often suffer from a combination of different PH groups 
such as groups 1, 2 and 3 in one patient, necessitating an 
even more tailored treatment schedule as in idiopathic PAH 
patients. However, in clinical trials patients with a combi-
nation of causes for PH are excluded and thus treatment 
of these patients is not evidence based. In our opinion, 
the main objective for future research should aim to im-
prove prognosis in this vulnerable group by focusing both 
on morbidity and mortality. Furthermore, translational 
research on vascular biomarkers and the use of nailfold 
capillaroscopy could help to define patients at greater risk 
for the development of PAH and could make personalized 
screening programmes possible.
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